SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:oru-56326"
 

Sökning: onr:"swepub:oai:DiVA.org:oru-56326" > The prognostic role...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005918naa a2200577 4500
001oai:DiVA.org:oru-56326
003SwePub
008170314s2015 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:15f11ed2-bb7c-4097-a174-8ba107a34456
009oai:DiVA.org:uu-256993
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-563262 URI
0247 a https://doi.org/10.1186/s12885-015-1479-32 DOI
0247 a https://lup.lub.lu.se/record/74771682 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2569932 URI
040 a (SwePub)orud (SwePub)lud (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Borgquist, Signeu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)ront-sbo
2451 0a The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study
264 c 2015-06-11
264 1b BioMed Central (BMC),c 2015
338 a print2 rdacarrier
520 a Background: HER2 is a well-established prognostic and predictive factor in invasive breast cancer. The role of HER2 in ductal breast carcinoma in situ (DCIS) is debated and recent data have suggested that HER2 is mainly related to in situ recurrences. Our aim was to study HER2 as a prognostic factor in a large population based cohort of DCIS with long-term follow-up. Methods: All 458 patients diagnosed with a primary DCIS 1986-2004 in two Swedish counties were included. Silver-enhanced in situ hybridisation (SISH) was used for detection of HER2 gene amplification and protein expression was assessed by immunohistochemistry (IHC) in tissue microarrays. HER2 positivity was defined as amplified HER2 gene and/or HER2 3+ by IHC. HER2 status in relation to new ipsilateral events (IBE) and Invasive Breast Cancer Recurrences, local or distant (IBCR) was assessed by Kaplan-Meier survival analyses and Cox proportional hazards regression models. Results: Primary DCIS was screening-detected in 75.5 % of cases. Breast conserving surgery (BCS) was performed in 78.6 % of whom 44.0 % received postoperative radiotherapy. No patients received adjuvant endocrine-or chemotherapy. The majority of DCIS could be HER2 classified (N = 420 (91.7 %)); 132 HER2 positive (31 %) and 288 HER2 negative (69 %)). HER2 positivity was related to large tumor size (P = 0.002), high grade (P < 0.001) and ER-and PR negativity (P < 0.001 for both). During follow-up (mean 184 months), 106 IBCRs and 105 IBEs were identified among all 458 cases corresponding to 54 in situ and 51 invasive recurrences. Eighteen women died from breast cancer and another 114 had died from other causes. The risk of IBCR was statistically significantly lower subsequent to a HER2 positive DCIS compared to a HER2 negative DCIS, (Log-Rank P = 0.03, (HR) 0.60 (95 % CI 0.38-0.94)). Remarkably, the curves did not separate until after 10 years. In ER-stratified analyses, HER2 positive DCIS was associated with lower risk of IBCR among women with ER negative DCIS (Log-Rank P = 0.003), but not for women with ER positive DCIS. Conclusions: Improved prognostic tools for DCIS patients are warranted to tailor adjuvant therapy. Here, we demonstrate that HER2 positive disease in the primary DCIS is associated with lower risk of recurrent invasive breast cancer.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Ductal carcinoma in situ (DCIS)
653 a HER2
653 a Prognostic marker
653 a Breast cancer
7001 a Zhou, Wenjingu Uppsala universitet,Institutionen för kirurgiska vetenskaper4 aut0 (Swepub:uu)wenzh820
7001 a Jirström, Karinu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-kji
7001 a Amini, Rose-Marieu Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)roseamin
7001 a Sollie, Thomasu Dept Pathol, Örebro University Hospital, Örebro, Sweden4 aut
7001 a Sorlie, Thereseu Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo Univ Hosp, Oslo, Norway4 aut
7001 a Blomqvist, Carlu Cent Hosp, Dept Oncol, Univ Helsinki, Helsinki, Finland4 aut
7001 a Butt, Salmau Lund University,Lunds universitet,Kirurgi,Forskargrupper vid Lunds universitet,Surgery,Lund University Research Groups4 aut0 (Swepub:lu)med-smb
7001 a Wärnberg, Fredriku Uppsala universitet,Endokrinkirurgi4 aut0 (Swepub:uu)fredwarn
7102 a Bröstcancer-genetikb Sektion I4 org
7730 t BMC Cancerd : BioMed Central (BMC)g 15q 15x 1471-2407
8564 u https://doi.org/10.1186/s12885-015-1479-3y Fulltext
8564 u https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-015-1479-3
8564 u https://portal.research.lu.se/files/3133904/8776892x primaryx freey FULLTEXT
8564 u http://www.ncbi.nlm.nih.gov/pubmed/26062614?dopt=Abstractx freey FULLTEXT
8564 u http://dx.doi.org/10.1186/s12885-015-1479-3x freey FULLTEXT
8564 u https://uu.diva-portal.org/smash/get/diva2:832564/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-56326
8564 8u https://doi.org/10.1186/s12885-015-1479-3
8564 8u https://lup.lub.lu.se/record/7477168
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-256993

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy